Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
24.64
+0.35 (1.44%)
At close: Apr 7, 2026, 4:00 PM EDT
24.98
+0.34 (1.38%)
Pre-market: Apr 8, 2026, 7:37 AM EDT
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 298 employees as of December 31, 2025. The number of employees increased by 28 or 10.37% compared to the previous year.
Employees
298
Change (1Y)
28
Growth (1Y)
10.37%
Revenue / Employee
$578,362
Profits / Employee
-$957,792
Market Cap
2.17B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 298 | 28 | 10.37% | 298 | 0 |
| Dec 31, 2024 | 270 | 86 | 46.74% | 270 | 0 |
| Dec 31, 2023 | 184 | 77 | 71.96% | 184 | 0 |
| Dec 31, 2022 | 107 | 48 | 81.36% | 107 | 0 |
| Dec 31, 2021 | 59 | 16 | 37.21% | 59 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| ADMA Biologics | 647 |
| Adaptive Biotechnologies | 624 |
| Agios Pharmaceuticals | 540 |
| Day One Biopharmaceuticals | 178 |
| Aurinia Pharmaceuticals | 128 |
| Definium Therapeutics | 106 |
| Tyra Biosciences | 87 |
SNDX News
- 4 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Syndax Announces Participation in March Investor Conferences - GlobeNewsWire
- 6 weeks ago - Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - GlobeNewsWire
- 2 months ago - Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 3 months ago - Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. - GlobeNewsWire
- 3 months ago - Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire